Yuka Negishi

Yotsuya Medical Cube, Yotsukaidō, Chiba, Japan

Are you Yuka Negishi?

Claim your profile

Publications (5)19.37 Total impact

  • Surgery for Obesity and Related Diseases 05/2010; 6(3):S45-S46. DOI:10.1016/j.soard.2010.03.255 · 4.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) for super morbid obesity in patients with an initial body mass index (BMI) of <50 or > or =50. Between October 2005 and January 2008, we performed LSG in 30 patients. There were 20 males and 10 females with a mean age of 38 years. Mean initial body weight and BMI were 139 kg and 49.1 kg/m(2), respectively. Sleeve gastrectomy was carried out using a linear stapler from the greater curvature of the antrum 5 cm proximal from the pyloric ring up to the angle of His alongside a 45-Fr. bougie. Laparoscopic procedures were performed successfully in all patients. The mean operation time was 92 min, and blood loss was minimal. The BMI change and weight loss at the 1-, 3-, 6-, 9-, 12-, and 18-month follow-up points of patients with an initial BMI of <50 and > or =50 were 34.2 and 57.4, 32.1 and 53.7, 29.6 and 50.8, 29.5 and 51.2, 27.8 and 52.2, and 29.7 and 45.5 kg/m(2) and 96.8 and 172.2, 89.5 and 157.0, 83.4 and 144.8, 84.0 and 145.4, 78.0 and 153.4, and 84.5 and 119.5 kg, respectively. The patients with a BMI of <50 obtained good outcomes, but weight loss reached a plateau at 9 months after surgery in patients with a BMI of > or =50. Postoperative complications included leakage, bleeding, stricture, and peritonitis in one patient each. There was no surgical mortality. Most of the co-morbidities improved after surgery. Sleeve gastrectomy is a feasible and safe treatment for super morbid obesity, but evaluation of long-term outcome is necessary to determine whether it is a durable procedure in terms of effectiveness. We expect that patients with a BMI of <50 are good candidates for LSG as a definitive treatment, and, if those with a BMI of > or =50 hope for further weight loss, a second-step procedure may be required.
    Obesity Surgery 10/2009; 19(10):1371-6. DOI:10.1007/s11695-008-9774-6 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Obesity and metabolic disorders related to it have become a serious problem in Asia. Furthermore, gastric cancer in Asia is one of the frequent diseases on which to perform treatments. We introduced the technique of laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG/DJB) for patients with a risk of gastric cancer and compared the results of our initial series with those of other procedures. Methods: Twenty-one patients underwent a LSG/DJB from April 2007 to November 2008. The mean preoperative weight and body mass index (BMI) were 108.0 kg and 41.0 kg/m(2), respectively. High risks of gastric cancer were determined as having a Helicobacter pylori positive with atrophic change of mucosa or a family history of gastric cancer. Operations were performed with five ports. Initially, SG and dissection of posterior wall of duodenum were carried out. Subsequently, DJB was added with 50-100 cm of biliopancreatic tract and 150-200 cm of alimentally tract. DJB consisted of a jejunojejunostomy created by a linear stapler and hand sewing closure and duodenojujunostomy by hand sewing with two layers. Results: A LSG/DJB was performed successfully in all patients. The mean operation time was 217 +/- 38 min. The weight loss and percent excess BMI loss for LSG/DJB were similar to those for laparoscopic Roux-en-Y gastric bypasses. There was no mortality; however, one patient had leakage from a staple line of esophagogastric junction and reqiured drainage and stenting. No dumping, stenosis, marginal ulcer, or nutritional problems were observed during postoperative follow-up. All of the main comorbidities improved after this procedure. Conclusion: LSG/DJB is a feasible, safe, and effective procedure for the treatment of morbidly obese patients with the risk of gastric cancer.
    Obesity Surgery 09/2009; 19(10). DOI:10.1007/s11695-009-9979-3 · 3.75 Impact Factor
  • Akiko Umezawa · Yuka Negishi · Eiji Kanehira
    Surgery for Obesity and Related Diseases 05/2009; 5(3). DOI:10.1016/j.soard.2009.03.146 · 4.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is steadily increasing in Asia due to factors such as a lack of exercise, adoption of a more Western diet, changing lifestyles, environments, or stresses. Even in Japan, this tendency is notable, and metabolic syndrome has become widely recognized. However, bariatric surgery is still uncommon in Japan. There are no adequate data regarding the experience and outcome of bariatric surgery in Asia. Here, we report on the current status of morbid obesity and the outcomes of bariatric surgery by a single surgeon in Japan. Between February 2002 and January 2008, we have performed laparoscopic bariatric surgery for morbid obesity in 178 cases. They consisted of laparoscopic Roux-en-Y gastric bypass (LRYGBP) in 105 cases, laparoscopic sleeve gastrectomy (LSG) in 26 cases, laparoscopic sleeve gastrectomy with duodenal jejunal bypass (LSG/DJB) in 14 cases, laparoscopic adjustable gastric banding (LAGB) in 13 cases, and laparoscopic biliopancreatic diversion with duodenal switch in one case under the same protocol of follow up. The first author of this paper performed all procedures. One hundred and thirty-eight patients with a follow-up of over 3 months after surgery were enrolled. LRYGBP accounted for 72% of all bariatric procedures. The reduction of weight and body mass index (BMI) in LRYGBP and LSG showed similar results. These outcomes were superior to those of LAGB. Percentage of excess BMI loss (%EBMIL) of LRYGBP showed greater reductions at follow-ups 6, 9, 12, and 18 months after surgery compared to that of LRYGBP and LAGB. All procedures resulted in over 50% of %EBMIL after 18 months of follow-up. There was no postoperative mortality within 30 days after surgery. Preoperative comorbidity including diabetes mellitus, hypertension, and hyperlipidemia were resolved or improved after surgery in most patients. In bariatric surgery, LRYGBP is the most effective treatment for morbid obesity, while LAGB has a low risk of postoperative complications. LSG is also a safe procedure for supermorbidly obese patients. We expect that bariatric surgery will be a common procedure for patients with morbid obesity in Japan.
    Obesity Surgery 05/2008; 18(11):1473-8. DOI:10.1007/s11695-008-9492-0 · 3.75 Impact Factor